Search This Blog

Tuesday, August 6, 2024

Walz left Guard battalion ‘hanging,’ ‘slithered out the door’ before Iraq deployment: vets

 Veterans have accused Minnesota Gov. Tim Walz of “embellishing” his military career and abandoning his National Guard battalion, highlighting that the now-vice presidential pick for the Democrats never served in combat and retired from service ahead of his unit’s 2005 deployment to Iraq.

In a letter posted to Facebook in 2018 as he first ran for governor, retired Command Sergeants Major Thomas Behrends and Paul Herr said Walz retired from his 24-year tenure in the National Guard after learning that his battalion would be deployed to Iraq, despite allegedly assuring his fellow troops he would join them.

Veterans have accused Minnesota Gov. Tim Walz of “embellishing” his military career and abandoning his National Guard battalion.Courtesy of Tim Walz

“On May 16th, 2005, [Walz] quit, betraying his country, leaving the 1-125th Field Artillery Battalion and its Soldiers hanging; without its senior Non-Commissioned Officer, as the battalion prepared for war,” Behrends and Herr wrote.

Walz, 60, wrapped his military career just in time for him to launch his political career the following year, successfully running for Congress in 2006.

Walz, 60, wrapped his military career just in time for him to launch his political career the following year.Getty Images

Behrends and Herr criticized him for leaving the National Guard for Congress despite being fully aware that he could have requested permission from the Pentagon to seek office while on active duty.

Democratic vice presidential nominee Minnesota Gov. Tim Walz prepares to depart from his temporary gubernatorial residence.Getty Images

Walz further dodged the necessary paperwork to ensure a smooth transition out of military service and “instead … slithered out the door,” the pair added, with his retirement filing showing “soldier not available for signature.”

The National Guard members also accused the now-two-term Minnesota governor of having “embellished and selectively omitted facts of his military career for years.”

The letter was first unearthed by the Daily Wire.

Still, Walz has said he has “an honorable record” — and other service members who led the same battalion have defended him.

“He was a great soldier,” Joseph Eustice, who served 32 years in the National Guard, told the Star Tribune in 2022.

“When he chose to leave, he had every right to leave,” added Eustice, who indicated that other attacks on Walz’s record may have been made by disgruntled soldiers who were passed up for promotions.

Walz has said he has “an honorable record.”US Army

Another National Guard member who served under Walz said that the future US lawmaker was eyeing a run for Congress earlier than 2005.

“Would the soldier look down on him because he didn’t go with us? Would the common soldier say, ‘Hey, he didn’t go with us, he’s trying to skip out on a deployment?’ And he wasn’t,” Al Bonnifield recalled to Minnesota Public Radio of Walz’s concerns about dipping out before the deployment to Iraq.

“He talked with us for quite a while on that subject. He weighed that decision to run for Congress very heavy [sic],” Bonnifeld added. “He loved the military, he loved the guard, he loved the soldiers he worked with.”

“We all do what we can. I’m proud I did 24 years,” Walz has said about his service.

Walz joined the National Guard after high school and had served in the 1st Battalion, 125th Field Artillery before his retirement, where he obtained the rank of command sergeant major.

During his subsequent tenure in Congress, Walz came out in opposition against then-President George W. Bush’s plans to increase troop levels in Iraq.

https://nypost.com/2024/08/06/us-news/tim-walz-embellished-military-career-for-years-dropped-from-national-guard-unit-ahead-of-iraq-deployment/

Goldman Heads on 'Interconnected Realities' Of Markets & Geopolitics, Looming Iran Strike

 The war drums in the Middle East are getting louder by the hour as the world braces for an imminent Iranian (or Iranian proxy forces) strike on Israel. The US faces the daunting task of defending Israel from Iranian strikes if deterrence missile defense shields fail, which could potentially ignite a regional conflict. 

Jared Cohen, President of Global Affairs and Co-Head of the Goldman Sachs Global Institute, and Sam Morgan, Global Head of FICC Sales and Co-Head of One Goldman Sachs, discussed Tuesday the latest developments in the Middle East, structural changes across the region, and how markets are responding to the overseas crisis as war risks soar. 

Here's the complete transcript of the conversation between Cohen and Morgan released for clients on Tuesday:

MORGAN:

Last month we witnessed a series of shocks and escalations in the Middle East, and tensions are only increasing. How have these developments changed the post-October 7 conflict in the Middle East?

COHEN:

A wider war has been possible since the beginning. In particular, a war between Israel and Hezbollah has been possible since October 8, when Hezbollah fired its first rockets after Hamas's attack. More than 80,000 Israelis have evacuated their homes in northern Israel since, and most remain displaced. The killing of 12 Druze children playing on a soccer field on July 27 made a larger war between the two sides much more likely.

An all-out war with Hezbollah could be more violent, for both Lebanon and Israel, than the conflict with Hamas has been to date. Hezbollah has an arsenal of 120,000 to 200,000 rockets and missiles, including hundreds of precision guided missiles and 65,000 short-range rockets. These munitions could strike cities throughout Israel, as well critical infrastructure, such as electricity grids.

Israel has also reshaped the war in the last few weeks. Despite ten months of conflict, Israel's longest since its War of Independence from 1948 – 1949, the Israel Defense Forces and intelligence services have shown themselves to still be tremendously capable. In retaliation for the Houthi drone attack on Tel Aviv, Israel's air force struck the Houthi-controlled Hudaydah port in faraway Yemen, refueling mid-air during the long-distance mission. The bomb that killed Hamas leader Ismail Haniyeh was reportedly planted in an Iranian Revolutionary Guard Corps (IRGC) guesthouse months ago. This was a shock for the Supreme Leader, who is aging and now never leaves the country. Combined with the elimination of Hamas leader Mohammed Deif and Hezbollah military commander Fuad Shukr, who played a role in the 1983 Marine Corps Barracks bombing in Beirut, and other targeted assassinations, Israel may be trying to retake the initiative and show Iran the unexpected and high costs of escalation.

MORGAN:

Many observers are expecting retaliation by Iran, possibly including a direct assault against Israel. Is such an attack likely, and are Israel, the US and their partners prepared for such an escalation?

COHEN:

We don't know the timing of a potential Iranian retaliation, and it's impossible to predict the scale with certainty. But a direct Iranian-led assault against Israel looks increasingly likely, and Israelis and their partners are preparing.

This is a very precarious moment for the region, and the risks are high. In April, Iran broke the geopolitical seal on direct confrontation, when it fired 170 drones, more than 30 cruise missiles, and more than 120 ballistic missiles against Israel. Israel reportedly struck back. After the killing of Haniyeh, on August 1 in Tehran, Supreme Leader Ayatollah Ali Khamenei met in Tehran with proxy groups from Iraq, Syria, and Lebanon to discuss retaliation against Israel.

What could make this potential attack different from April's? There is an increased level of coordination among Iran and its proxies across seven fronts. In addition, it's possible that Iran could use more munitions, attack different targets, and engage in prolonged assaults that could overwhelm Israel's defense systems, or even use its proxies to simultaneously attack US forces in Syria or Iraq, where several servicemembers were injured earlier this week. Iran or its proxies could also attack Israel or Jewish targets abroad, such when Hezbollah attacked a Jewish community center in Argentina in 1994 or attempted to execute a plot in Brazil at the beginning of the current war. And the closer we get to the US election, the more uncertainty there will likely be about US politics and engagement in the region.

The preparations to defend against Iranian attacks are extensive. Israel and its partners intercepted almost all Iran's missiles and drones four months ago, and Jerusalem and its allies and partners are working together again. Countries are urging their citizens to leave Lebanon. The US and Arab countries have in recent days sent envoys and messages to Tehran to work to deescalate the situation, so far without success. The commander of US Central Command arrived in Israel earlier this week. The US is moving more defensive assets to the region, including the USS Abraham Lincoln aircraft carrier strike group, which will replace the USS Theodore Roosevelt. Israel is likely closely coordinating with its Sunni Arab neighbors – what Prime Minister Netanyahu now refers to as the "Abraham Alliance" – to defend against their shared rival in Iran. And, depending on the scale of the attack, Israeli Defense Minister Yoav Gallant has said the military is ready for a "swift transition to offense."

MORGAN:

How do the events of the last month fit into Iran's broader regional strategy, and do you expect any change in Iran's calculus?

COHEN:

In my view, Iran relies on proxies to achieve its objectives to attack Israel, push the US out of Iraq and Syria, and become the dominant power in the Middle East. Those objectives likely have not changed. But, as April's Iranian attack against Israel showed, Tehran is now more prepared than it was before to engage in direct confrontation, rather than relying exclusively on proxies and covert action. If Iran directly attacks Israel, the US, or their allies and partners in the next few days or weeks, we will be able to better calculate if Tehran is seeking a wider, all-out regional war, with all the costs that would bring, or if its strategy is to save face and continue the conflict at its current levels. An attack is increasingly likely, but as Israel's actions over the last few weeks have shown, escalation presents enormous risks to the regime in Iran as well.

MORGAN:

How do you think about the broader geopolitical setup in the Middle East and the incentives and positioning of each of the key regional actors?

COHEN:

There have been two key strategic questions since October 7. First, can Iran and its proxies create a new normal in the Middle East, with constant conflict and attrition that wears down Israel, the US and their allies and partners, without imposing unacceptable direct costs on Tehran? And second, can they break apart an emerging Israel-Sunni Arab bloc and become the dominant power in the region?

On the former, Iran has so far succeeded. The damage that Iran and its proxies have done to Israel, Palestinians, and populations throughout the region is enormous. The costs to Iran – including attacks on Iranian soil and the targeting of IRGC commanders – have so far not been high enough to change Tehran's overall strategy.

But Iran has not yet succeeded in breaking apart the Israel-Sunni bloc. We saw that in April, when Israel coordinated its defense with countries like Saudi Arabia and Jordan. The Abraham Accords between Israel and the United Arab Emirates, Bahrain, Morocco, and even Sudan continue to hold. The incentives for this bloc – as diverse as the actors are – to not let Iran dominate the Middle East are clear. And if anything, this geopolitical test has reinforced the direction of travel for wealthy Gulf countries, who have been pushing for economic integration and diversification and for greater influence on the global stage. To succeed, however, Israel and Washington's partners in the Gulf will likely need US support.

COHEN:

How have markets reacted to the rise in geopolitical tensions?

MORGAN:

There has been a significant re-pricing of regional assets (e.g. Israel CDS, USDILS FX, ILS interest rate swaps) since mid-July, but the impact on commodities has been limited (and the oil price is down on the month). Equity markets (SPX in particular, but notably Nasdaq and Topix as well) and bond markets (such as short dated UST) have re-priced meaningfully in recent weeks, and Middle Eastern escalations have contributed to a sense of market nervousness, but the primary drivers of market moves have been a changing market perception around US recession risk, US tech earnings reports, questions about the timing and magnitude of the impact of developments in Gen(AI), and de-risking of crowded trades.

COHEN:

If the market reactions to the events in the Middle East have (so far) been limited, what escalations in the region could shift how the markets view the current crisis and its effects on global growth? What lessons have we learned that could be useful for future geopolitical shocks?

MORGAN:

The primary market nexus through which Middle Eastern tensions could have global growth impact would be via the oil market (as was the case in the 1970s). To date, the oil market has largely shrugged off geopolitical concerns and focused on the impact on demand of US and China slowdowns (and the potential impact of the US election on supply). A further escalation could impact oil markets to the upside if critical oil infrastructure were endangered. The broader lesson remains that the markets focus first and foremost on the economy and policy. Geopolitical tensions have major impacts on specific companies, sectors (e.g. defense), and countries, but for global impacts there needs to be a direct knock-on to growth, inflation (e.g. via oil prices), or monetary and fiscal policy. The focus for now will remain on the US economy and areas of potential concern (such as low-end consumers, and housing), the extent of the Fed' put' and their willingness to ease rates fast (e.g. the possibility of 50bp increment cuts), and big tech AI expenditure and earnings.

https://www.zerohedge.com/geopolitical/middle-east-brink-goldman-heads-discuss-interconnected-realities-markets-geopolitics

'Drugstores Toy With New Looks as Usual Way of Doing Business Hits Challenges'

 America's drugstores are testing smaller locations and more ways to offer care as price-sensitive shoppers look elsewhere.

Customers may see Walgreens stores that are one-fourth the size of a regular location or CVS drugstores with entire primary clinics stuffed inside. If these experiments succeed, the new stores might improve access to care and create a more lasting connection with customers, analysts say.

"Everyone looks at healthcare and says, 'Oh yeah, it's a market that's ripe for disruption,'" said Neil Saunders, managing director of consulting and data analysis firm GlobalData. "But it isn't easy to disrupt."

Walgreens CEO Tim Wentworth said recently that his company could close a "significant portion" of underperforming stores in the next few years. CVS Health is going through a round of closings. Rite Aid has filed for bankruptcy. Thousands of independent drugstores have closedopens in a new tab or window over the past 5 years.

The closures can leave gaps: An Associated Press analysis published in Juneopens in a new tab or window found that urban neighborhoods that are majority Black and Latino have fewer pharmacies per capita than white majority neighborhoods.

There are still more than 30,000 drugstores scattered around the country, but even Walgreens executives admit that the market is overbuilt.

The stores have struggled with increased competition from Amazon and lower-price options like Walmart or Dollar Tree. They're also dealing with theft, growing costs, and thinner prescription reimbursement.

Some are responding with new looks. Walgreens is testing a store in Chicago that has digital kiosks where customers place orders. A separate desk offers pickup of items ordered at the kiosks or online.

The company also has opened about 100 mini drugstores focused on health and wellness and featuring store-brand merchandise. Walgreens started testing these stores in 2019 and plans to add more this year.

Walgreens spokesman Jim Cohn said shopper preferences are shifting, and the company aims "to meet them where, when, and how they want to shop."

Saunders notes these stores are less expensive to run and allow the company to serve areas without enough people to support a bigger store.

At one of these locations in Indianapolis, only four short aisles separate the front door and the pharmacy counter in the back. Healthy snacks, vitamins, first aid supplies, and the usual mix of antacids and Advil fill its shelves.

But there are no magazines and only small selections of greeting cards and beauty products at the store, which is closed on Sundays and sits about a half mile from a vacant Walgreens.

Customer Leonard King has visited several times. He says his prescriptions are ready on time, and the store seems to have decent supplies.

"Being a diabetic, sometimes medicines are hard to get," the 67-year-old Indianapolis resident said.

But King also said he misses being able to shop for things like toiletry items that can be found at bigger stores.

The selection of retail items also is smaller at some CVS Health stores that include Oak Street Health primary care clinics. The company plans to open about 25 of these combinations this year and 11 more next year, with either full-sized or smaller clinics in the stores.

The clinics can have primary care doctors, social workers, and people to help with insurance coverage. They specialize in treating patients with Medicare Advantage plans, which are privately run versions of the government's coverage program mostly for people age 65 and older.

CVS Health says it is putting the clinics in areas that need primary care. It is targeting big cities like Chicago, New York, and Dallas with its initial rollout.

"If we can invest more upfront for the patients who need it, by increasing access, improving quality of care, we can keep patients healthier," company executive Mike Pykosz said.

Making things easier for patients helps build relationships between store staff and customers and can lead to repeat business, noted Arielle Trzcinski, a principal analyst at Forrester who covers healthcare.

Independent drugstores also have been polishing their healthcare reputations. They are expanding immunizations and testing, spurred partly by increased business they saw during the COVID-19 pandemic, said Kurt Proctor, PhD, of the National Community Pharmacists Association.

Some also are adding doctor's offices or specializing in diabetes care. Proctor said they are doing what they have always done: adapting to community needsopens in a new tab or window.

"There are 19,000 (independent) stores across the country and no two of them are exactly alike," he said.

Diving into healthcare isn't new for drugstores. They started adding small clinics more than 20 years ago. CVS Health has been on a health kick since it quit selling tobacco in 2014.

As many as a quarter of drugstores could eventually wind up with big health clinics, especially those located in densely populated areas, said Jeff Jonas, a portfolio manager at Gabelli Funds who follows the industry.

But he cautioned that the idea is still unproven.

Walgreens has closed VillageMD primary care clinics just a few years after it launched plans to add hundreds to its stores. Analysts say companies are still learning what makes money and resonates with customers.

One thing they know for certain: Drugstores are no longer "America's convenience destination" like they used to be, Saunders said.

"That really, over the past 10 to 15 years, has unwound," he said.

https://www.medpagetoday.com/pharmacy/pharmacy/111385

'Tim Walz Beat COVID Skeptic Doc in 2022 Race for Governor'

 

Scott Jensen, MD, spoke out against vaccines, masking, and school and business closures

Minnesota Gov. Tim Walz (D) -- who is now Kamala Harris' pick for vice president -- won reelection in 2022 after defeating Scott Jensen, MD, a family physician who became known for his controversial COVID stances.

Jensen, who served as a state senator from 2017 to 2021, had a reputation for being a moderate Republican before the COVID pandemic, according to the Associated Pressopens in a new tab or window.

During the pandemic, he refused to get vaccinated against COVIDopens in a new tab or window because he had antibodies from a mild infection in August 2020, even giving up his hospital privilegesopens in a new tab or window to avoid vaccine requirements. He also reportedly called for civil disobedience over masks and promoted unproven treatments such as ivermectin, AP reportedopens in a new tab or window.

Jensen also was "quietly" a member of America's Frontline Doctorsopens in a new tab or window (AFLD), one of the most outspoken groups against COVID public health policies. Jensen even signed onto a federal lawsuitopens in a new tab or window brought by AFLD seeking to halt COVID vaccines for some kidsopens in a new tab or window.

"I've definitely been a [COVID] skeptic, to be sure," Jensen said during the third and final gubernatorial debateopens in a new tab or window in October 2022, describing what prompted him to become one. He said a doctor told him a patient had died due to a fall, but COVID had been listed as a "contributing condition" on the patient's death certificate.

He reached out to the state's health department as the vice chair of the department of human services committee at the time in search of an explanation, but received no response, Jensen said.

"All I got was 3 months later, for the first time in my life, I was being investigated, my medical license," Jensen said during the debate. "That's been five times, but it's never been done because of a healthcare service I provided. It's because someone didn't like my politics."

The five investigations by the Minnesota Board of Medical Practice were the result of complaints about Jensen's stances on COVID, but none resulted in disciplinary action. Jensen sued the board -- in state court and in federal court -- for free speech violations due to its investigations. A judge dismissed the federal lawsuitopens in a new tab or window in April, and the state complaint is set to go to trial in November.

During that debate he also spoke out against school lockdowns, shutting down businesses, the "denial of natural immunity," and "flip-flopping" on the vaccine, in terms of it ultimately not completely preventing infection or blocking transmission of the virus.

When asked who he would turn to for medical advice if he were elected governor, Jensen named other physicians with controversial COVID stances -- Harvey Risch, MD, PhDopens in a new tab or window, of Yale University in New Haven, Connecticut; John Ioannidis, MD, of Stanford University in California; radiologist Scott Atlas, MDopens in a new tab or window, also of Stanford University; and cardiologist Peter McCullough, MDopens in a new tab or window.

Healthcare was a frequent topic during all three debates, illuminating Walz's position on key healthcare topics including drug prices, abortion, and opioid abuse.

Healthcare has become "way too expensive" Walz said during the second debateopens in a new tab or window, hosted by Gray Television. He emphasized that abortion is a constitutionally protected right in Minnesota, and he pounced on an admission by Jensen that pharmaceutical company perks, such as meals, influenced his prescribing of opioids.

Walz also frequently faced questions about the state's "Feeding Our Future" scandal, in which 70 people ultimately were accused of stealing $250 million in federal relief aid meant for children. The U.S. Department of Justice (DOJ) dubbed itopens in a new tab or window the "largest COVID-19 fraud scheme in the nation."

The individuals allegedly diverted the funds to buy things like luxury cars, houses, jewelry, and a coastal resort property abroad, according to the DOJopens in a new tab or window. As of June, 18 defendants have pleaded guilty and five were convicted by a federal jury.

"When there were those putting out false information, internet myths, ivermectin, whatever you have," Walz said, "this was a life-and-death situation and food security was a top priority. The vast majority of those [grantees] delivered and did an incredible job."

https://www.medpagetoday.com/washington-watch/washington-watch/111395

'3 Years After COVID Hospitalization, Cognitive Problems Persist and Worsen'

 

  • Some early COVID patients showed cognitive deficits up to 3 years after hospitalization.
  • Symptoms at 2 to 3 years were not predicted by severity of acute COVID-19 illness.
  • Many changed jobs after they were hospitalized due to cognitive problems.

Up to 3 years after being hospitalized with acute SARS-CoV-2 during the first months of the pandemic, some patients still had mild to severe cognitive and psychiatric outcomes, data from the COVID Fog (C-Fog) study showed.

At the 2- to 3-year point, a group of early COVID survivors scored significantly lower than expected across all cognitive domains, showing an average deficit equivalent to 10 IQ points (average score 0.71 standard deviations below the mean, P<0.0001), reported Maxime Taquet, PhD, of the University of Oxford in England, and co-authors in Lancet Psychiatryopens in a new tab or window.

One in nine had objective signs of severe cognitive deficits that equated to a difference of 30 IQ points.

At 2 to 3 years, most participants reported at least mild anxiety (74.5%), fatigue (53.5%), or subjective cognitive decline (52.1%). More than a fifth said these symptoms were severe. Symptoms at 2 to 3 years were not predicted by the severity of acute COVID-19, but by the degree of recovery at 6 months.

More than a quarter of participants (26.9%) changed occupations after having COVID, with poor health being the most common reason. Occupation changes were associated with cognitive deficits.

"The findings show that problems affecting attention and memory -- as well as fatigue, depression, and anxiety -- continue to afflict some people even 3 years after COVID-19 infection, especially those who had not recovered well by 6 months," co-author Paul Harrison, FRCPsych, also of the University of Oxford, told MedPage Today.

"These results apply only to people who needed acute hospital admission when they had COVID-19," Harrison emphasized. "We suspect, but do not know, whether similar kinds of problems might affect the much larger number of people who did not get hospitalized."

C-Fog was a study nested within the PHOSP-COVIDopens in a new tab or window study of hospitalized U.K. COVID patients. Of 2,469 PHOSP-COVID patients invited to participate in the C-Fog study, 475 provided data at the 2- to 3-year follow-up. All had SARS-CoV-2 infection before the Delta variant emerged.

C-Fog is one of few studies to prospectively follow early hospitalized COVID patients. Its findings add to data showing higher rates of cognitive decline and dementia among older patients hospitalized with COVID-19, noted Tracy Vannorsdall, PhD, of Johns Hopkins Medicine in Baltimore, and co-authors in an accompanying editorialopens in a new tab or window.

"The observation of cognitive decline 2-3 years after infection among hospitalized patients in this study of relatively young COVID-19 survivors (mean age 58.3 years) is particularly concerning," Vannorsdall and colleagues wrote.

"The primary study finding -- that the degree of symptom improvement achieved within the first 6 months after illness predicts later neuropsychiatric dysfunction -- suggests a window of opportunity for positively altering the trajectory of patient outcomes," they added.

Prior studies showed that 10.7% of hospitalized patients discharged after severe SARS-CoV-2 infection in Brazilopens in a new tab or window had long-term impairment that persisted for 1 year. Among COVID-19 survivors discharged from Wuhan hospitalsopens in a new tab or window in early 2020, the incidence of cognitive impairment 12 months later was 12.45%.

The C-Fog study included mostly men (59.8%) with a mean age of 58 who were discharged with a COVID diagnosis between Feb. 1, 2020, and March 31, 2021.

In this group, depression, anxiety, and fatigue were worse at 2 to 3 years than at 6 months or 12 months, with evidence of both worsening of existing symptoms and emergence of new symptoms, Taquet and colleagues reported.

The degree of recovery at 6 months explained 35% to 49% of the variance in anxiety, depression, fatigue, and subjective cognitive decline symptoms at 2 to 3 years. A profile linking elevated D-dimer relative to C-reactive proteinopens in a new tab or window during acute COVID with subjective cognitive deficits at 6 months also explained 7% to 17% of the variance at 2 to 3 years.

Objective cognitive deficits at 2 to 3 years were not predicted by any factor tested except cognitive deficits at 6 months, which explained about 11% of their variance.

Occupation changes were linked with both objective cognitive deficits (OR 1.51, 95% CI 1.04-2.22 for every standard deviation decrease in overall cognitive score) and subjective cognitive decline (OR 1.54, 95% 1.21-1.98 for every point increase on the 20-item Cognitive Change Index questionnaire).

The findings were limited to patients hospitalized with COVID early in the pandemic and may not apply to those infected with later variants or who were vaccinated. The low response rate and high symptom prevalence suggest that selection bias may have occurred.

Disclosures

This work was funded by MQ Mental Health Research, the Wolfson Foundation, U.K. Research and Innovation, the National Institute for Health and Care Research (NIHR), and the NIHR Oxford Health Biomedical Research Centre.

Taquet is an NIHR clinical lecturer. Co-authors reported relationships with nonprofit organizations, academic centers, and industry.

One editorialist reported a relationship with the NIH; the others had no relevant disclosures.

Primary Source

Lancet Psychiatry

Source Reference: opens in a new tab or windowTaquet M, et al "Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the U.K." Lancet Neurol 2024; DOI: 10.1016/S2215-0366(24)00214-1.

Secondary Source

Lancet Psychiatry

Source Reference: opens in a new tab or windowVannorsdall TD, et al "Neuropsychiatric and work outcomes after COVID-19 hospitalization" Lancet Neurol 2024; DOI: 10.1016/S2215-0366(24)00250-5.


https://www.medpagetoday.com/neurology/longcovid/111401